Search

Royalty Pharma PLC (Class A)

Open

SectorHealthcare

59.04 0.8

Overview

Share price change

24h

Current

Min

57.99

Max

59.13

Key metrics

By Trading Economics

Income

-61M

295M

Sales

8.6M

631M

P/E

Sector Avg

30.639

62.58

EPS

1.3

Dividend yield

1.54

Profit margin

46.733

Employees

100

EBITDA

112M

563M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+6.81% upside

Dividends

By Acuity

Dividend yield

Sector Avg

1.54%

2.19%

Next Earnings

5 sie 2026

Next Dividend date

10 wrz 2026

Next Ex Dividend date

14 sie 2026

Market Stats

By TradingEconomics

Market Cap

3.2B

33B

Previous open

58.24

Previous close

59.04

News Sentiment

By Acuity

50%

50%

144 / 340 Ranking in Healthcare

Royalty Pharma PLC (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 lip 2026, 19:11 UTC

News
Event

Royalty Pharma acquires a royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront payment. Shares are trading roughly flat.

21 lip 2026, 17:51 UTC

Royalty Pharma PLC shares are higher today, tracking broader market gains, with unusually high trading volume noted. No specific news was identified for the movement.

20 lip 2026, 19:21 UTC

Royalty Pharma PLC shares are lower as the Pharmaceuticals sector faces downward pressure, with unusually high trading volume noted today.

Peer Comparison

Price change

Royalty Pharma PLC (Class A) Forecast

Price Target

By TipRanks

6.81% upside

12 Months Forecast

Average 62.4 USD  6.81%

High 66 USD

Low 58 USD

Based on 6 Wall Street analysts offering 12 month price targets forRoyalty Pharma PLC (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Sentiment

By Acuity

144 / 340 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
help-icon Live chat